Vaccine adjuvants: putting innate immunity to workRobert L Coffman
Dynavax Technologies Corporation, Berkeley, CA 94710, USA
Immunity 33:492-503. 2010
..However, the larger challenge is to develop vaccines that generate strong T cell immunity with purified or recombinant vaccine antigens...
- TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus
Cristiana Guiducci
Dynavax Technologies Corporation, 2929 Seventh Street, Suite 100, Berkeley, California 94710, USA
Nature 465:937-41. 2010
..These findings unveil a new role for self nucleic acid recognition by TLRs and indicate that inhibitors of TLR7 and 9 signalling could prove to be effective corticosteroid-sparing drugs...
Development of TLR inhibitors for the treatment of autoimmune diseasesFranck J Barrat
Dynavax Technologies Corporation, Berkeley, CA 94710, USA
Immunol Rev 223:271-83. 2008
..We describe novel inhibitors of these receptors and provide evidence to support their use as novel therapeutic agents for autoimmunity...
- Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9
Cristiana Guiducci
Dynavax Technologies Corporation, Berkeley, CA 94710, USA
J Exp Med 207:2931-42. 2010
..These data suggest that inhibitors of TLR7 and TLR9 signaling have potential therapeutic application for the treatment of interface dermatitis...
- CpG-containing immunostimulatory DNA sequences elicit TNF-alpha-dependent toxicity in rodents but not in humans
John D Campbell
Dynavax Technologies Corporation, Berkeley, California 94710, USA
J Clin Invest 119:2564-76. 2009
..These data demonstrate that ISS induce rodent-specific TNF-alpha-dependent toxicity that is absent in humans and reflective of differential TLR9 expression patterns in rodents versus humans...
- PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation
Cristiana Guiducci
Dynavax Technologies Corporation, Berkeley, CA 94710, USA
J Exp Med 205:315-22. 2008
..Thus, PI3K selectively controls type I IFN production by regulating IRF-7 nuclear translocation in human pDCs and could serve as a novel target to inhibit pathogenic type I IFN in autoimmune diseases...
Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptomsFranck J Barrat
Dynavax Technologies Corporation, Berkeley, CA 94710, USA
Eur J Immunol 37:3582-6. 2007
..These data demonstrate that in addition to its ability to block IFN-alpha, IRS 954 can reduce symptoms in a lupus model and thus represents a promising therapeutic agent for the treatment of SLE...
- Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions
Jason D Marshall
Dynavax Technologies Corporation, Berkeley, California, USA
J Leukoc Biol 73:781-92. 2003
....
- Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Holger Kanzler
Dynavax Technologies, 2929 Seventh Street, Suite 100, Berkeley, California 94710, USA
Nat Med 13:552-9. 2007
..As recognition grows of the role of inappropriate Toll-like receptor stimulation in inflammation and autoimmunity, significant efforts have begun to develop antagonists to Toll-like receptors as well...
- Superior activity of the type C class of ISS in vitro and in vivo across multiple species
Jason D Marshall
Dynavax Technologies Corporation, Berkeley, California 94710, USA
DNA Cell Biol 24:63-72. 2005
..In conclusion, we have shown CpG-C to exert several types of immune functions across multiple species, and this novel class is thus an attractive candidate for ISS-based therapeutic strategies...
- A minimal human immunostimulatory CpG motif that potently induces IFN-gamma and IFN-alpha production
Karen Fearon
Dynavax Technologies Corporation, Berkeley, CA 94710, USA
Eur J Immunol 33:2114-22. 2003
..These results describe a novel technique for formulating active, but very short, ISS oligodeoxynucleotide that allows for the dissection and characterization of minimal immunostimulatory CpG motifs...
- IL-10 regulates plasmacytoid dendritic cell response to CpG-containing immunostimulatory sequences
Omar Duramad
Dynavax Technologies, 717 Potter St, Ste 100, Berkeley, CA 94710, USA
Blood 102:4487-92. 2003
..The 3 distinct classes of ISS differed with respect to induction of PDC maturation and T-cell priming capacity. IL-10 regulated PDC activation but did not inhibit the subsequent T-cell-priming ability of PDCs already activated by ISS...
- Biomarkers measuring the activity of Toll-like receptor ligands in clinical development programs
Paul Sims
Dynavax Technologies, Berkeley, CA 94710, USA
Methods Mol Biol 517:415-40. 2009
....
- Nonhuman primate models of asthma
Robert L Coffman
Dynavax Technologies, Berkeley, CA 94710, USA
J Exp Med 201:1875-9. 2005
..We advocate more extensive use of nonhuman primate asthma models to reconcile these differences between man and mouse...
- Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation
Omar Duramad
Dynavax Technologies, Berkeley, CA 94710, USA
J Immunol 174:5193-200. 2005
..IRS can also inhibit a complex pathological response to ISS, as shown by protection from death after massive systemic inflammation induced by a CpG-containing oligodeoxynucleotides...
- Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation
Cristiana Guiducci
Dynavax Technologies Corporation, Berkeley, CA 94710, USA
J Exp Med 203:1999-2008. 2006
..This establishes that the primary determinant of TLR9 signaling is not valency but endosomal location and demonstrates a strict compartmentalization of the biological response to TLR9 activation in PDCs...
- Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus
Franck J Barrat
Dynavax Technologies Corporation, Berkeley, CA 94710, USA
J Exp Med 202:1131-9. 2005
..These inhibitors of TLR signaling thus represent novel therapeutic agents with potential for the treatment of lupus...
- Novel chimeric immunomodulatory compounds containing short CpG oligodeoxyribonucleotides have differential activities in human cells
Jason D Marshall
Dynavax Technologies Corporation, 717 Potter Street, Suite 100, Berkeley, CA 94710, USA
Nucleic Acids Res 31:5122-33. 2003
....
- Origins of the T(H)1-T(H)2 model: a personal perspective
Robert L Coffman
Dynavax Technologies, Berkeley, California 94710, USA
Nat Immunol 7:539-41. 2006
..Robert L. Coffman recounts how his work on immunoglobulin E regulation along with data from Tim Mosmann on the functional heterogeneity of T cell clones led to the T helper type 1-T helper type 2 hypothesis...
- Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction
Edith M Hessel
Dynavax Technologies, Berkeley, CA 94710, USA
J Exp Med 202:1563-73. 2005
..Thus, inhibition by ISS of allergic responses can be explained by two novel mechanisms that culminate in the inhibition of the principal sources of type 2 cytokines in the airways...
